LRRC32

LRRC32

LRRC32 Informations sur la molécule

Molecule Name
Transforming growth factor beta activator LRRC32
Alias de la molécule
GARP,Garpin,D11S833E
Drug Development Progress
Nombre de médicaments cliniques7
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 3 Clinical
Alias de la cible
Leucine Rich Repeat Containing 32,D11S833E,Garpin,Leucine-Rich Repeat-Containing Protein 32,LRRC32,Transforming Growth Factor Beta Activator LRRC32,GARP,Glycoprotein A Repetitions Predominant
Contexte de la molécule
Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells. LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells. The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation.

LRRC32 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
LivmoniplimabMGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115Phase 3 ClinicalArgenx Se
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours
Details
Anti-GARP Chimeric Antigen Receptor T Cell Therapy (Ohio State University Comprehensive Cancer Center)Phase 1 ClinicalOhio State University Comprehensive Cancer Center
Glioma
Details
PBA-0111PBA-0111Phase 1 ClinicalPure Biologics SA
Sarcoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
HLX-6018HLX-6018; HLX6018Phase 1 Clinical
Idiopathic Pulmonary Fibrosis
Details
JYB-1907JYB-1907Phase 1 ClinicalJiangxi Jemincare Group Co Ltd
Solid tumours
Details
DS-1055DS-1055; DS-1055aPhase 1 ClinicalDaiichi Sankyo Co Ltd
Neoplasms; Solid tumours
Details
HLX-60HLX-60Phase 1 Clinical
Lymphoma; Solid tumours
Details